Zogenix to Present at Jefferies 2014 Global Healthcare Conference
30. Mai 2014 09:00 ET
|
Zogenix
SAN DIEGO, May 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...
Zogenix Closes Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International
19. Mai 2014 07:30 ET
|
Zogenix
SAN DIEGO, May 19, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...
Zogenix Reports First Quarter 2014 Financial Results
08. Mai 2014 16:01 ET
|
Zogenix
Recent Business Highlights
Commercial and medical affairs organization began educational efforts to prescribers and pharmacists for Zohydro™ ER (hydrocodone bitartrate) extended-release...
Zogenix Reports Granting of Inducement Awards
02. Mai 2014 16:05 ET
|
Zogenix
SAN DIEGO, May 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Zogenix Announces Conference Call and Webcast to Present First Quarter 2014 Financial Results
30. April 2014 08:30 ET
|
Zogenix
SAN DIEGO, April 30, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...
Zogenix Announces Sale of SUMAVEL(R) DosePro(R) Migraine Therapy to Endo International
24. April 2014 07:30 ET
|
Zogenix
SAN DIEGO, April 24, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...
Zogenix Reports Granting of Inducement Awards
02. April 2014 08:30 ET
|
Zogenix
SAN DIEGO, April 2, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Zogenix Appoints James Breitmeyer to Its Board of Directors
26. März 2014 08:30 ET
|
Zogenix
SAN DIEGO, March 26, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related conditions and central...
Dr. Marsha Stanton Receives 2014 American Academy of Pain Medicine Distinguished Service Award
07. März 2014 08:30 ET
|
Zogenix
SAN DIEGO, March 7, 2014 (GLOBE NEWSWIRE) -- Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing and commercializing products for the treatment of pain-related and central nervous system...
Zogenix Reports Fourth Quarter and Full Year 2013 Financial Results
05. März 2014 16:05 ET
|
Zogenix
Business Highlights and Milestones
Raised net proceeds of $64.5 million in a public offering of common stock
Expanded medical and commercial leadership teams, and sales force to 150...